Regeneron Pharmaceuticals, Inc.REGNNASDAQ
LOADING
|||
Operating Income Performance
Strong compound growth.
Left:
||||
Profit from core business operations before interest and taxes
Latest
$3.99B
↑ 12% above average
Average (9y)
$3.57B
Historical baseline
Range
High:$8.95B
Low:$1.25B
CAGR
+13.7%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $3.99B | -8.2% |
| 2023 | $4.35B | -19.3% |
| 2022 | $5.39B | -39.8% |
| 2021 | $8.95B | +150.1% |
| 2020 | $3.58B | +61.9% |
| 2019 | $2.21B | -12.8% |
| 2018 | $2.53B | +21.9% |
| 2017 | $2.08B | +56.3% |
| 2016 | $1.33B | +6.3% |
| 2015 | $1.25B | - |